Here’s whether Cue Biopharma, Inc. (CUE) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+19.83% over 10 days); strong 1-year return of +34.9%; 3-month momentum positive (+198.3%); rising volume confirms the move (1.82x 30d avg). Currently 19.9% off its 52-week high. Score: +7/7.
CUE is in a confirmed uptrend, trading above both its 50-day ($11.20) and 200-day ($16.64) moving averages. An RSI of 65.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +34.9% compares to +24.4% for SPY (beat the market by 10.5%).
$10,000 invested 1 year ago→ $13,488 today
vs. S&P 500 (SPY) — same period beat market by 10.5%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($16.64)
✓Above 50-day MA ($11.20)
✓RSI(14) neutral zone (30–70) — currently 65.0
✓Positive return (+34.9%)
!Within 10% of period high (−19.9%)
Period Range $30.42
$4.97$38.00
RSI (14) 65.0
0 · OversoldOverbought · 100
Key Metrics
Price$30.42
Period Return+34.9%
Period High$38.00
Period Low$4.97
Drawdown−19.9%
MA-50$11.20
MA-200$16.64
RSI (14)65.0
Avg Volume (30d)1.3M
vs. SPYbeat by 5.8%
Return Rank#437 of 1245
Trend Signals
Price is above the 200-day moving average ($16.64)